PMID- 30325558
OWN - NLM
STAT- MEDLINE
DCOM- 20190102
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 109
IP  - 12
DP  - 2018 Dec
TI  - Functionally impaired follicular helper T cells induce regulatory B cells and 
      CD14(+) human leukocyte antigen-DR(-) cell differentiation in non-small cell lung 
      cancer.
PG  - 3751-3761
LID - 10.1111/cas.13836 [doi]
AB  - Non-small cell lung cancer (NSCLC) represents one of the most common and 
      aggressive cancers worldwide, as it typically displays irreversible progression 
      and poor prognosis. Interaction between programmed death 1 (PD-1) and its ligand, 
      PD-L1, plays important roles in tumor immunology. Follicular helper T (Tfh) cells 
      have characteristically high PD-1 expression; thus, in the present study, we 
      investigated the role of circulating Tfh cells and their correlation with 
      disease-free survival after tumor resection in NSCLC. We found significantly 
      higher number of Tfh cells but lower serum interleukin (IL)-21 levels in NSCLC 
      patients, especially in those with advanced stage (III and IV), indicating that 
      the function of Tfh cells to produce IL-21 was impaired. Further analysis showed 
      that the increase in Tfh cells was attributable to an expansion of the PD-1(+) 
      -Tfh2 and PD-1(+) -Tfh17 subtypes. Functional analysis showed that Tfh cells from 
      NSCLC patients induced the differentiation of regulatory B cells and CD14(+) 
      human leukocyte antigen (HLA)-DR(-) cells. Interestingly, the number of Tfh1 
      subtypes in NSCLC patients was negatively correlated with disease-free survival 
      after tumor resection. In short, the high number and abnormal function of Tfh 
      cells could cause further immunosuppression and lead to tumor development in 
      NSCLC. Rescuing Tfh functions therefore represents a potential therapeutic 
      strategy in NSCLC.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Qiu, Liannv
AU  - Qiu L
AUID- ORCID: 0000-0001-9853-8391
AD  - Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, 
      People's Hospital of Hangzhou Medical College, Hangzhou, China.
FAU - Yu, Qinhua
AU  - Yu Q
AD  - Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, 
      People's Hospital of Hangzhou Medical College, Hangzhou, China.
FAU - Zhou, Yonglie
AU  - Zhou Y
AD  - Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, 
      People's Hospital of Hangzhou Medical College, Hangzhou, China.
FAU - Zheng, Sujie
AU  - Zheng S
AD  - Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, 
      People's Hospital of Hangzhou Medical College, Hangzhou, China.
FAU - Tao, Jiaojiao
AU  - Tao J
AD  - School of Laboratory Medicine and Life Science, Wenzhou Medical University, 
      Wenzhou, China.
FAU - Jiang, Qian
AU  - Jiang Q
AD  - College of Medical Technology, Zhejiang Chinese Medical University, Hangzhou, 
      China.
FAU - Yuan, Guorong
AU  - Yuan G
AD  - Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital 
      of Hangzhou Medical College, Hangzhou, China.
LA  - eng
GR  - No: Y18H200014/Zhejiang Provincial Natural Science Fund/
GR  - No: 2012/Zhejiang Provincial Program for the Cultivation of High-level Innovative 
      Health Talents/
PT  - Journal Article
DEP - 20181114
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interleukins)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - MKM3CA6LT1 (interleukin-21)
SB  - IM
EIN - Cancer Sci. 2019 Feb;110(2):834-835. PMID: 30716196
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - B-Lymphocytes, Regulatory/*cytology/immunology
MH  - Carcinoma, Non-Small-Cell Lung/blood/immunology/pathology/*surgery
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Disease-Free Survival
MH  - Female
MH  - HLA-DR Antigens/*metabolism
MH  - Humans
MH  - Interleukins/blood
MH  - Lipopolysaccharide Receptors/blood/*metabolism
MH  - Lung Neoplasms/blood/immunology/pathology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Programmed Cell Death 1 Receptor/metabolism
MH  - T-Lymphocytes, Helper-Inducer/*cytology/immunology
MH  - Treatment Outcome
PMC - PMC6272090
OTO - NOTNLM
OT  - CD14+ HLA-DR-
OT  - Follicular helper T cell
OT  - interleukin-21
OT  - non-small cell lung cancer
OT  - regulatory B cell
EDAT- 2018/10/17 06:00
MHDA- 2019/01/03 06:00
PMCR- 2018/12/01
CRDT- 2018/10/17 06:00
PHST- 2018/05/07 00:00 [received]
PHST- 2018/10/08 00:00 [revised]
PHST- 2018/10/09 00:00 [accepted]
PHST- 2018/10/17 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
PHST- 2018/10/17 06:00 [entrez]
PHST- 2018/12/01 00:00 [pmc-release]
AID - CAS13836 [pii]
AID - 10.1111/cas.13836 [doi]
PST - ppublish
SO  - Cancer Sci. 2018 Dec;109(12):3751-3761. doi: 10.1111/cas.13836. Epub 2018 Nov 14.